Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 3
1968 3
1969 3
1970 5
1971 4
1972 4
1973 2
1974 3
1976 2
1977 2
1978 3
1979 3
1980 8
1981 8
1982 11
1983 12
1984 7
1985 23
1986 14
1987 14
1988 14
1989 6
1990 10
1991 12
1992 9
1993 14
1994 10
1995 5
1996 10
1997 10
1998 14
1999 12
2000 8
2001 12
2002 11
2003 8
2004 14
2005 4
2006 5
2007 10
2008 8
2009 6
2010 12
2011 19
2012 7
2013 7
2014 10
2015 10
2016 17
2017 18
2018 17
2019 20
2020 19
2021 19
Text availability
Article attribute
Article type
Publication date

Search Results

491 results
Results by year
Filters applied: . Clear all
Page 1
An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
Ishiguro T, Sano Y, Komatsu SI, Kamata-Sakurai M, Kaneko A, Kinoshita Y, Shiraiwa H, Azuma Y, Tsunenari T, Kayukawa Y, Sonobe Y, Ono N, Sakata K, Fujii T, Miyazaki Y, Noguchi M, Endo M, Harada A, Frings W, Fujii E, Nanba E, Narita A, Sakamoto A, Wakabayashi T, Konishi H, Segawa H, Igawa T, Tsushima T, Mutoh H, Nishito Y, Takahashi M, Stewart L, ElGabry E, Kawabe Y, Ishigai M, Chiba S, Aoki M, Hattori K, Nezu J. Ishiguro T, et al. Among authors: tsushima t. Sci Transl Med. 2017 Oct 4;9(410):eaal4291. doi: 10.1126/scitranslmed.aal4291. Sci Transl Med. 2017. PMID: 28978751
TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study.
Kuboki Y, Nishina T, Shinozaki E, Yamazaki K, Shitara K, Okamoto W, Kajiwara T, Matsumoto T, Tsushima T, Mochizuki N, Nomura S, Doi T, Sato A, Ohtsu A, Yoshino T. Kuboki Y, et al. Among authors: tsushima t. Lancet Oncol. 2017 Sep;18(9):1172-1181. doi: 10.1016/S1470-2045(17)30425-4. Epub 2017 Jul 28. Lancet Oncol. 2017. PMID: 28760399 Clinical Trial.
Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer.
Kato K, Doki Y, Ura T, Hamamoto Y, Kojima T, Tsushima T, Hironaka S, Hara H, Kudo T, Iwasa S, Muro K, Yasui H, Minashi K, Yamaguchi K, Ohtsu A, Kitagawa Y. Kato K, et al. Among authors: tsushima t. Cancer Sci. 2020 May;111(5):1676-1684. doi: 10.1111/cas.14380. Epub 2020 Apr 29. Cancer Sci. 2020. PMID: 32160365 Free PMC article. Clinical Trial.
Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
Sakai D, Taniguchi H, Sugimoto N, Tamura T, Nishina T, Hara H, Esaki T, Denda T, Sakamoto T, Okuda H, Satoh T, Tsushima T, Makiyama A, Tsuda T, Hosokawa A, Kuramochi H, Tokunaga S, Moriwaki T, Yasui H, Ishida H, Tsuji A, Otsu S, Shimokawa H, Baba E, Sato M, Matsumoto S, Ozaki Y, Shinozaki K, Tamagawa H, Goto M, Kadowaki S, Fujii H, Koh Y, Yamazaki K, Hironaka S, Kishimoto J, Boku N, Hyodo I, Muro K. Sakai D, et al. Among authors: tsushima t. Eur J Cancer. 2020 Aug;135:11-21. doi: 10.1016/j.ejca.2020.04.014. Epub 2020 Jun 8. Eur J Cancer. 2020. PMID: 32526634 Clinical Trial.
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).
Yamazaki K, Nagase M, Tamagawa H, Ueda S, Tamura T, Murata K, Eguchi Nakajima T, Baba E, Tsuda M, Moriwaki T, Esaki T, Tsuji Y, Muro K, Taira K, Denda T, Funai S, Shinozaki K, Yamashita H, Sugimoto N, Okuno T, Nishina T, Umeki M, Kurimoto T, Takayama T, Tsuji A, Yoshida M, Hosokawa A, Shibata Y, Suyama K, Okabe M, Suzuki K, Seki N, Kawakami K, Sato M, Fujikawa K, Hirashima T, Shimura T, Taku K, Otsuji T, Tamura F, Shinozaki E, Nakashima K, Hara H, Tsushima T, Ando M, Morita S, Boku N, Hyodo I. Yamazaki K, et al. Among authors: tsushima t. Ann Oncol. 2016 Aug;27(8):1539-46. doi: 10.1093/annonc/mdw206. Epub 2016 May 13. Ann Oncol. 2016. PMID: 27177863 Free article. Clinical Trial.
A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors.
Doi T, Muro K, Ishii H, Kato T, Tsushima T, Takenoyama M, Oizumi S, Gemmoto K, Suna H, Enokitani K, Kawakami T, Nishikawa H, Yamamoto N. Doi T, et al. Among authors: tsushima t. Clin Cancer Res. 2019 Nov 15;25(22):6614-6622. doi: 10.1158/1078-0432.CCR-19-1090. Epub 2019 Aug 27. Clin Cancer Res. 2019. PMID: 31455681 Free article. Clinical Trial.
TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
Bando H, Kotani D, Tsushima T, Hara H, Kadowaki S, Kato K, Chin K, Yamaguchi K, Kageyama SI, Hojo H, Nakamura M, Tachibana H, Wakabayashi M, Fukutani M, Togashi Y, Fuse N, Nishikawa H, Kojima T. Bando H, et al. Among authors: tsushima t. BMC Cancer. 2020 Apr 20;20(1):336. doi: 10.1186/s12885-020-06716-5. BMC Cancer. 2020. PMID: 32312286 Free PMC article. Clinical Trial.
Syncope After Percutaneous Coronary Intervention.
Tsushima T, Sahadevan J, Intini A. Tsushima T, et al. JAMA Cardiol. 2019 Nov 1;4(11):1170-1171. doi: 10.1001/jamacardio.2019.3306. JAMA Cardiol. 2019. PMID: 31532445 Review. No abstract available.
Unusual Cause of Cardiac Arrest.
Tsushima T, Patel TR, Sahadevan J. Tsushima T, et al. JAMA Intern Med. 2021 Apr 1;181(4):542-543. doi: 10.1001/jamainternmed.2020.8370. JAMA Intern Med. 2021. PMID: 33464284 No abstract available.
491 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page